Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Albert Einstein Medical Center
176
mi
from 02139
Bronx, NY
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Albert Einstein Medical Center
176
mi
from 02139
Bronx, NY
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Monter Cancer Center
173
mi
from 02139
Lake Success, NY
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Monter Cancer Center
173
mi
from 02139
Lake Success, NY
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Blumenthal Cancer Center
718
mi
from 02139
Charlotte, NC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Blumenthal Cancer Center
718
mi
from 02139
Charlotte, NC
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Cancer Centers of North Carolina
608
mi
from 02139
Raleigh, NC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Cancer Centers of North Carolina
608
mi
from 02139
Raleigh, NC
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Oncology Hematology Care, Inc.
726
mi
from 02139
Blue Ash, OH
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Oncology Hematology Care, Inc.
726
mi
from 02139
Blue Ash, OH
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
The Mark H. Zangmeister Center
635
mi
from 02139
Columbus, OH
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
The Mark H. Zangmeister Center
635
mi
from 02139
Columbus, OH
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Oregon Health and Science University
2530
mi
from 02139
Portland, OR
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Oregon Health and Science University
2530
mi
from 02139
Portland, OR
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
South Carolina Oncology Associates, PA
789
mi
from 02139
Columbia, SC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
South Carolina Oncology Associates, PA
789
mi
from 02139
Columbia, SC
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Chattanooga Oncology Hematology Associates
915
mi
from 02139
Chattanooga, TN
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Chattanooga Oncology Hematology Associates
915
mi
from 02139
Chattanooga, TN
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
The West Clinic, PC
1124
mi
from 02139
Memphis, TN
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
The West Clinic, PC
1124
mi
from 02139
Memphis, TN
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Tennessee Oncology, PLLC
973
mi
from 02139
Nashville, TN
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Tennessee Oncology, PLLC
973
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Texas Oncology, PA
1545
mi
from 02139
Dallas, TX
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Texas Oncology, PA
1545
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Utah Cancer Specialists
2090
mi
from 02139
Salt Lake City, UT
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Utah Cancer Specialists
2090
mi
from 02139
Salt Lake City, UT
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Virginia Oncology Associates
467
mi
from 02139
Norfolk, VA
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Virginia Oncology Associates
467
mi
from 02139
Norfolk, VA
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Virginia Cancer Institute
478
mi
from 02139
Richmond, VA
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Virginia Cancer Institute
478
mi
from 02139
Richmond, VA
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Karmanos Cancer Institute
609
mi
from 02139
Detroit, MI
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Karmanos Cancer Institute
609
mi
from 02139
Detroit, MI
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Washington University School of Medicine
1036
mi
from 02139
St. Louis, MO
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Washington University School of Medicine
1036
mi
from 02139
St. Louis, MO
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
SUNY Upstate Medical University
260
mi
from 02139
Syracuse, NY
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
SUNY Upstate Medical University
260
mi
from 02139
Syracuse, NY
Click here to add this to my saved trials
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated:  1/14/2016
Cancer Centers of the Carolinas
802
mi
from 02139
Greenville, SC
Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination With Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men With Metastatic Castrate Resistant Prostate Cancer (AFFINITY)
Status: Enrolling
Updated: 1/14/2016
Cancer Centers of the Carolinas
802
mi
from 02139
Greenville, SC
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1299
mi
from 02139
Hot Springs, AR
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1299
mi
from 02139
Hot Springs, AR
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1140
mi
from 02139
Jonesboro, AR
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1140
mi
from 02139
Jonesboro, AR
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
2690
mi
from 02139
Greenbrae, CA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
2690
mi
from 02139
Greenbrae, CA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1771
mi
from 02139
Colorado Springs, CO
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1771
mi
from 02139
Colorado Springs, CO
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1261
mi
from 02139
Bonita Springs, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1261
mi
from 02139
Bonita Springs, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1213
mi
from 02139
Bradenton, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1213
mi
from 02139
Bradenton, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1251
mi
from 02139
Cape Coral, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1251
mi
from 02139
Cape Coral, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
1245
mi
from 02139
Ft. Meyers, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
1245
mi
from 02139
Ft. Meyers, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1273
mi
from 02139
Naples, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1273
mi
from 02139
Naples, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1229
mi
from 02139
Port Charlotte, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1229
mi
from 02139
Port Charlotte, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1222
mi
from 02139
Sarasota, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1222
mi
from 02139
Sarasota, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1233
mi
from 02139
Venice, FL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1233
mi
from 02139
Venice, FL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
934
mi
from 02139
Atlanta, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
934
mi
from 02139
Atlanta, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
861
mi
from 02139
Augusta, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
861
mi
from 02139
Augusta, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
946
mi
from 02139
Macon, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
946
mi
from 02139
Macon, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
932
mi
from 02139
Marietta, GA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
932
mi
from 02139
Marietta, GA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
846
mi
from 02139
Chicago, IL
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
846
mi
from 02139
Chicago, IL
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1117
mi
from 02139
Minneapolis, MN
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1117
mi
from 02139
Minneapolis, MN
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1854
mi
from 02139
Billings, MT
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1854
mi
from 02139
Billings, MT
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
140
mi
from 02139
Albany, NY
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
140
mi
from 02139
Albany, NY
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
143
mi
from 02139
East Setauket, NY
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
143
mi
from 02139
East Setauket, NY
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
704
mi
from 02139
Kettering, OH
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
704
mi
from 02139
Kettering, OH
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
801
mi
from 02139
Greenville, SC
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
801
mi
from 02139
Greenville, SC
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
939
mi
from 02139
Nashville, TN
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
939
mi
from 02139
Nashville, TN
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1546
mi
from 02139
Dallas, TX
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1580
mi
from 02139
Ft. Worth, TX
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1580
mi
from 02139
Ft. Worth, TX
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
1490
mi
from 02139
Tyler, TX
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
1490
mi
from 02139
Tyler, TX
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
2256
mi
from 02139
Spokane, WA
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
2256
mi
from 02139
Spokane, WA
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
966
mi
from 02139
Marshfield, WI
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
966
mi
from 02139
Marshfield, WI
Click here to add this to my saved trials
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated:  1/15/2016
4638
mi
from 02139
Belo Horizonte,
Study of Irofulven in Patients With Hormone-refractory Prostate Cancer
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients
Status: Enrolling
Updated: 1/15/2016
4638
mi
from 02139
Belo Horizonte,
Click here to add this to my saved trials
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated:  1/15/2016
Clinical Research Facility
2275
mi
from 02139
Tucson, AZ
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
A Phase III Trial to Test the Efficacy of ZD4054(Zibotentan), an Endothelin A Receptor Antagonist, Versus Placebo in Patients With Hormone Resistant Prostate Cancer (HRPC) and Bone Metastasis Who Are Pain Free and Mildly Symptomatic.
Status: Enrolling
Updated: 1/15/2016
Clinical Research Facility
2275
mi
from 02139
Tucson, AZ
Click here to add this to my saved trials